- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient | 2 | GlobeNewswire (USA) | ||
| 08.05. | Longeveron Q1 2025 slides: promising clinical data amid financial headwinds | 1 | Investing.com | ||
| 08.05. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update | 43 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to... ► Artikel lesen | |
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 08.05. | Longeveron Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 28.03. | Longeveron files $70M mixed securities shelf | 1 | Seeking Alpha | ||
| 20.03. | Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease | 220 | GlobeNewswire (Europe) | Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design... ► Artikel lesen | |
| 14.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease | 195 | GlobeNewswire (Europe) | Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data... ► Artikel lesen | |
| 03.03. | Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 28.02. | Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update | 317 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more... ► Artikel lesen | |
| 28.02. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.02. | Longeveron Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 18.02. | Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B | 1 | GlobeNewswire (USA) | ||
| 30.01. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.24 | Longeveron to Present at Biotech Showcase 2025 | 3 | GlobeNewswire (USA) | ||
| 27.10.24 | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 140 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 10.07.24 | Pre-market Movers: VivoPower, NaaS Technology, Ampco-Pittsburgh, LegalZoom.com, Longeveron | 835 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green VivoPower International PLC (VVPR) is up over 90%... ► Artikel lesen | |
| 10.07.24 | Longeveron Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease | 606 | GlobeNewswire (Europe) | MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and... ► Artikel lesen | |
| 13.06.24 | Pre-market Movers: Neo-Concept International, Longeveron, BioRestorative Therapies, DDC Enterprise, J.Jill | 830 | AFX News | BUENOS AIRES (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).In the Green Neo-Concept International Group Holdings Limited... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,80 | +0,36 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| CUREVAC | 3,094 | +0,72 % | EQS-News: CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 32,600 | 0,00 % | Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? | ||
| OCUGEN | 0,629 | -0,82 % | Ocugen Provides Business Update with First Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate... ► Artikel lesen | |
| CYTODYN | 0,332 | 0,00 % | CytoDyn Inc.: CytoDyn Releases ESMO Breast Cancer Meeting Poster | ||
| SOL GLOBAL INVESTMENTS | 0,060 | -0,99 % | SOL Global Investments Corp.: Sol Global Announces $1M USD Strategic Investment into McQueen Labs Inc. ("MCQ Markets") for Digital Tokenization of Investment-Grade Collector Cars | Toronto, Ontario--(Newsfile Corp. - May 9, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional... ► Artikel lesen | |
| CELLECTIS | 1,300 | -5,93 % | Cellectis Reports Financial Results for the First Quarter 2025 | Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 7,214 | -3,74 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
| CERUS | 1,085 | -5,65 % | Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update | CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,829 | 0,00 % | WINDTREE THERAPEUTICS INC /DE/ - 10-Q, Quarterly Report | ||
| APTEVO THERAPEUTICS | 0,401 | 0,00 % | Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | 9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trialsMipletamig triplet combination continues to outperform standard doublet benchmarkNo cytokine release... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,268 | -7,59 % | Harvard Bioscience, Inc.: Harvard Bioscience Announces First Quarter 2025 Financial Results | HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2025. Jim Green,... ► Artikel lesen | |
| ENTERA BIO | 1,710 | -3,72 % | Entera Bio Ltd.: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates | JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key... ► Artikel lesen | |
| XBRANE BIOPHARMA | 0,024 | 0,00 % | Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report January-March 2025 | Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report January-March 2025, is as of today, available on the Company's website, www.xbrane.com.
FINANCIAL OVERVIEW FIRST QUARTER 2025* • Revenue amounted... ► Artikel lesen | |
| QIAGEN | 37,615 | +0,36 % | ANALYSE-FLASH: UBS belässt Qiagen auf 'Neutral' - Ziel 48 Dollar | ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.